PTO/SB/96 (08-06)
Approved for use through 09/30/2008. OMB 0651-0031
U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displeys a valid OMB control number.
STATEMENT UNDER 37 CFR 3.73(b) Atty. Docket No. 2159.2350001
Applicant/Patent Owner: Mitchell E. REFF et al.
Application No./Patent No.: 6,893,636 Filed/Issue Date: May 17, 2005
Entitled: Gamma-1 and Gamma-3 Anti-Human CD23 Monoclonal Antibodies and Use Thereof as Therapeutics
Biogen Idec MA Inc. a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. I the assignee of the entire right, title, and interest or
an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is
in the patent application/patent identified above by virtue of either:
A. An assignment from the inventor(s) of the petent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Real Frame or for which a copy there of is attached.
OR B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
See I in Addendum To:
From: See 2 in Addendum. To: BIOCEN IDEC MA INC. The document was recorded in the United States Patent and Trademark Office at Reel 0.11505. Frame 0.921 or for which a copy thereof is attached.
From: To: The document was recorded in the United States Patent and Trademark Office at Reel Frame from or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.
☑ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. INOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTC. Sage MPEP 302.09! 302.09! Output Description: Output D
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. 9 March 2009
Signature AND Y BLOOKES Date (47-6719-2000 Telephone Number
Printed or Typed Name VICE PLESIDENT CHIEF IP COUNSEL Telephone Number

This collection of information is required by 3T CFR 3.73(b). The information is required to obtain or retein a benefit by the public which is to be required by the public which is the second of the USFTO to process) an application. Confidentially is governed by 3S U.S.C. 122 and 3T CFR 1.17 bit. 11. The USFTO is processed to the USFTO to processed an application. Confidentially is governed by 3S U.S.C. 122 and 3T CFR 1.17 bit. 11. The USFTO is propertied upon the individual case. As used to complete with other marker suggested for reducing the benefit was every opportunity upon the individual case. As used to complete with other marker suggested for reducing the benefit was characteristic or the USFTO is used to complete with other marker suggested and the USFTO is used to complete with other marker suggested and the USFTO is used to complete with other markers and the USFTO is used to the USFTO is

Addendum

- 1. Mitchell E. REFF, William S. KLOETZER and Takehiko NAKAMURA
- 2. IDEC PHARMACEUTICALS CORPORATION AND SEIKAGAKU CORPORATION